ADVM-022-10
Showing 1 - 25 of >10,000
Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)
Enrolling by invitation
- Diabetic Macular Edema
- Diabetic Retinopathy
- ADVM-022
-
Beverly Hills, California
- +6 more
Nov 4, 2022
Neovascular Age-related Macular Degeneration Trial in United States (ADVM-022)
Recruiting
- Neovascular Age-related Macular Degeneration
- ADVM-022
-
Phoenix, Arizona
- +4 more
Sep 8, 2022
Diabetic Macular Edema, Diabetic Retinopathy Trial in Puerto Rico, United States (6E11 vg/eye of ADVM-022, 2E11 vg/eye of
Active, not recruiting
- Diabetic Macular Edema
- Diabetic Retinopathy
- 6E11 vg/eye of ADVM-022
- +2 more
-
Phoenix, Arizona
- +13 more
Jan 10, 2022
Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration Trial in United States (ADVM-022)
Active, not recruiting
- Wet Age-related Macular Degeneration
- Neovascular Age-related Macular Degeneration
- ADVM-022
-
Bakersfield, California
- +10 more
Mar 21, 2022
Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]
Enrolling by invitation
- Wet Age-related Macular Degeneration
- Neovascular Age-related Macular Degeneration
- ADVM-022
-
Bakersfield, California
- +8 more
Dec 23, 2021
Alpha 1-Antitrypsin Deficiency Trial in Gainesville, Charleston (ADVM-043)
Completed
- Alpha 1-Antitrypsin Deficiency
- ADVM-043
-
Gainesville, Florida
- +1 more
Aug 3, 2022
Migraine Disorders Trial (Rizatriptan 5 mg, Rizatriptan 10 mg, Standard Care)
Completed
- Migraine Disorders
- Rizatriptan 5 mg
- +2 more
- (no location specified)
Feb 1, 2022
Migraine Headache Trial (rizatriptan benzoate (MK0462), Comparator: )
Completed
- Migraine Headache
- rizatriptan benzoate (MK0462)
- Comparator: placebo
- (no location specified)
Feb 1, 2022
Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL) Trial (Fludarabine (30 mg/m^2), Cyclophosphamide (500 mg/m^2), CRG-022
Not yet recruiting
- Cancer
- Relapsed/Refractory Large B-cell Lymphoma (LBCL)
- Fludarabine (30 mg/m^2)
- +2 more
- (no location specified)
Jul 25, 2023
Tumors, Metastatic Cancer, Advanced Cancer Trial in United States (Niraparib, TSR-042, Carboplatin-Paclitaxel)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in China (ICP-022, Chlorambucil, Rituximab)
Recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- ICP-022
- +2 more
-
Bengbu, Anhui, China
- +55 more
Mar 25, 2022
Melanoma Stage III, Melanoma Stage IV Trial in Washington, Boston, Pittsburgh (Dostarlimab (TSR-042) (singly), Dostarlimab
Recruiting
- Melanoma Stage III
- Melanoma Stage IV
- Dostarlimab (TSR-042) (singly)
- Dostarlimab (TSR-042) and TSR-022 (combination)
-
Washington, District of Columbia
- +2 more
Feb 22, 2022
Herpes Zoster Trial in Tartu (HZ/su vaccine)
Recruiting
- Herpes Zoster
- HZ/su vaccine
-
Elkridge, Maryland
- +47 more
Jan 6, 2023
Advanced/Metastatic Solid Tumors Trial in Australia, China (ATG-022)
Not yet recruiting
- Advanced/Metastatic Solid Tumors
-
Adelaide, Australia
- +3 more
Jan 30, 2023
Pachyonychia Congenita Trial in New Brighton (PTX-022)
Recruiting
- Pachyonychia Congenita
-
New Brighton, MinnesotaMinnesota Clinical Study Center
Dec 1, 2022
Non-Cystic Fibrosis Bronchiectasis Trial in Worldwide (Brensocatib 10 mg, Brensocatib 25 mg, Placebo)
Recruiting
- Non-Cystic Fibrosis Bronchiectasis
- Brensocatib 10 mg
- +2 more
-
Birmingham, Alabama
- +416 more
Jan 24, 2023
Orthodontic Appliance Complication Trial in Baghdad (Insignia™ twin brackets, Maestro® 3D Ortho Studio software (Discovery,
Completed
- Orthodontic Appliance Complication
- Insignia™ twin brackets
- +2 more
-
Baghdad, Iraqcollage of dentistry-Baghdad university
Sep 21, 2022
Adult Primary Liver Cancer, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer Trial in
Recruiting
- Adult Primary Liver Cancer
- +2 more
- TSR-022 and TSR-042
-
Honolulu, HawaiiUniversity of Hawaii
Sep 22, 2021
Clear Cell Renal Cell Carcinoma Trial in Worldwide (Belzutifan, Pembrolizumab, Placebo)
Recruiting
- Clear Cell Renal Cell Carcinoma
- Belzutifan
- +2 more
-
Duarte, California
- +250 more
Jan 27, 2023